Date | Time | Source | Headline | Symbol | Company |
05/17/2024 | 11:58AM | GlobeNewswire Inc. | AB Science communique un rectificatif sur les comptes consolidés au 31 décembre 2023 | EU:AB | Ab Science |
05/15/2024 | 2:16PM | GlobeNewswire Inc. | AB Science reports its revenues for the year 2023 and provides an update on its activities | EU:AB | Ab Science |
05/15/2024 | 2:16PM | GlobeNewswire Inc. | AB Science reports its revenues for the year 2023 and provides an update on its activities | EU:AB | Ab Science |
05/15/2024 | 2:16PM | GlobeNewswire Inc. | AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2023 et présente un point sur ses activités | EU:AB | Ab Science |
05/13/2024 | 12:08PM | GlobeNewswire Inc. | AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036 | EU:AB | Ab Science |
05/13/2024 | 12:08PM | GlobeNewswire Inc. | AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036 | EU:AB | Ab Science |
05/13/2024 | 12:08PM | GlobeNewswire Inc. | AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036 | EU:AB | Ab Science |
05/07/2024 | 12:05PM | GlobeNewswire Inc. | AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient | EU:AB | Ab Science |
05/07/2024 | 12:05PM | GlobeNewswire Inc. | AB Science: | EU:AB | Ab Science |
05/07/2024 | 12:05PM | GlobeNewswire Inc. | AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient | EU:AB | Ab Science |
05/02/2024 | 1:14PM | GlobeNewswire Inc. | AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB Science | EU:AB | Ab Science |
05/02/2024 | 1:14PM | GlobeNewswire Inc. | AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science | EU:AB | Ab Science |
05/02/2024 | 1:14PM | GlobeNewswire Inc. | AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science | EU:AB | Ab Science |
04/30/2024 | 12:56PM | GlobeNewswire Inc. | AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023 | EU:AB | Ab Science |
04/30/2024 | 12:56PM | GlobeNewswire Inc. | AB Science announces a slight delay in the publication of its 2023 annual financial report | EU:AB | Ab Science |
04/30/2024 | 12:56PM | GlobeNewswire Inc. | AB Science announces a slight delay in the publication of its 2023 annual financial report | EU:AB | Ab Science |
04/03/2024 | 12:08PM | GlobeNewswire Inc. | AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS | EU:AB | Ab Science |
04/03/2024 | 12:08PM | GlobeNewswire Inc. | AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA | EU:AB | Ab Science |
03/13/2024 | 7:58AM | GlobeNewswire Inc. | AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease | EU:AB | Ab Science |
03/13/2024 | 7:58AM | GlobeNewswire Inc. | AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune | EU:AB | Ab Science |
03/13/2024 | 7:58AM | GlobeNewswire Inc. | AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease | EU:AB | Ab Science |
03/07/2024 | 9:20AM | GlobeNewswire Inc. | AB Science propose un résumé de la conférence virtuelle qui s’est tenue le 4 mars 2024, avec pour objectif de faire le point sur le développement d'AB Science | EU:AB | Ab Science |
03/07/2024 | 9:20AM | GlobeNewswire Inc. | AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development | EU:AB | Ab Science |
03/07/2024 | 9:20AM | GlobeNewswire Inc. | AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development | EU:AB | Ab Science |
03/06/2024 | 2:21PM | GlobeNewswire Inc. | AB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre part | EU:AB | Ab Science |
03/06/2024 | 2:21PM | GlobeNewswire Inc. | AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company | EU:AB | Ab Science |
03/06/2024 | 2:21PM | GlobeNewswire Inc. | AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company | EU:AB | Ab Science |
03/01/2024 | 12:07PM | GlobeNewswire Inc. | AB Science tiendra une conférence virtuelle le lundi 4 mars 2024, de 18h30 à 19h30 | EU:AB | Ab Science |
03/01/2024 | 12:07PM | GlobeNewswire Inc. | AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET | EU:AB | Ab Science |
03/01/2024 | 12:07PM | GlobeNewswire Inc. | AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET | EU:AB | Ab Science |